ClinicalTrials.gg
Not yet recruitingNCT06351540Updated Oct 16, 2026

Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance

A Phase 1 interventional study of Cannabis in Cannabis Use, Impaired Driving and Cognitive Impairment, sponsored by Johns Hopkins University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Johns Hopkins University · Phase 1, Interventional, and Basic science

How we know

Updated Oct 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Cognitive Dysfunction by Johns Hopkins University — 13 open to participants now, 15 under way, 1 of them phase 3. Cognitive Dysfunction · Johns Hopkins University.

Planned enrollment
19th of 33
40 · median 52
Started
2026
with 2 others
Phase 1
4 of 34
3 open now
Primary completion
2027-07
later than 4 of 14 live
Registered
28th of 34
by date

Among the 34 studies in Cognitive Dysfunction by Johns Hopkins University, this one is the 19th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 4 of the 14 other live ones, and was the 28th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

13 of the 34 studies in Cognitive Dysfunction by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Cognitive Dysfunction by Johns Hopkins University, or all of them as a file.
02

Study summary

The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.

03

Conditions studied

  • Cannabis Use
  • Impaired Driving
  • Cognitive Impairment

Keywords

  • cannabis
  • THC
  • impairment
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion criteria: Healthy non-treatment seeking adults (age 18 to 60, N = 40) who report
  • (a) infrequent cannabis use defined as at least one reported use in the past year with a negative THC urine toxicology at baseline, or
  • (b) report frequent cannabis use defined as > 5 days per week for > 1 year with a positive THC urine toxicology at baseline.

These criteria were selected to target individuals with low and high-frequency cannabis use in order to examine the direct effect of tolerance on study outcome measures.

Exclusion criteria

Exclusion Criteria:

  • (1) meet criteria for substance use disorders other than tobacco, cannabis, or caffeine,
  • (2) are currently receiving or interested in immediately receiving behavioral treatment or medication for cannabis cessation,
  • (3) current use of any medications that could affect study outcomes,
  • (4) test positive for drugs of abuse (other than cannabis) and/or breath alcohol test at study admission,
  • (5) have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity,
  • (6) are currently pregnant, planning to become pregnant in the next three months or are currently breastfeeding,
  • (7) have a history of cardiac arrhythmias or vasospastic disease (e.g. Prinzmetal's angina), or (8) are currently enrolled in another clinical trial or have received any drug as part of a research study within 30 days of study participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Placebo comparator
    0 mg THC

    Inhaled Cannabis - 0 mg THC

    Drug: Cannabis

  • Experimental
    5 mg THC

    Inhaled cannabis - 5 mg THC

    Drug: Cannabis

  • Experimental
    30 mg THC

    Inhaled cannabis - 30 mg THC

    Drug: Cannabis

Interventions

06

What researchers measure

Primary outcomes

  1. Commission Errors

    The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Commission errors is measured by calculating the number of trials participants incorrectly push the spacebar in the presence of "X" stimulus.

    Time frame: pre-administration, post-administration, 2, 4 hours

  2. Omission Errors

    The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Omission errors is measured by calculating the number of trials participants fail to push the spacebar in the presence of a letter that is not an "X" stimulus.

    Time frame: pre-administration, post-administration, 2, 4 hours

  3. Reaction Time

    The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Reaction time is measured by calculating the duration between the presentation of a letter other than "X", and the correct response of a spacebar push.

    Time frame: pre-administration, post-administration, 2, 4 hours

  4. Reaction Time Standard Error

    The Conners Continuous Performance Test (CPT) will be used to assess sustained attention. Reaction time standard error is measured by calculating the standard error of the mean of the reaction time.

    Time frame: pre-administration, post-administration, 2, 4 hours

  5. Visuomotor Index

    The visuomotor index score is calculated by mathematically integrating five measures of oculomotor fixation performance and two measures of accuracy into a single score during fixation and accuracy tasks, respectively. Test of visual fixation to measure microsaccades, spontaneous nystagmus, and gaze-evoked nystagmus.

    Time frame: pre-administration, post-administration, 2, 4 hours

Secondary outcomes

  1. Saccade Speed

    Measures how quickly participants look back and forth between two spots as possible during the oculomotor task.

    Time frame: Pre-administration, post-administration, 2, 4 hours

  2. Visually Guided Oculomotor Performance

    Measures how quickly and accurately participants move their eyes to a cue as soon as it appears on the oculomotor task.

    Time frame: Pre-administration, post-administration, 2, 4 hours

  3. Antisaccade

    Measures voluntary eye movement in the direction opposite to the side in which a visual cue is presented.

    Time frame: Pre-administration, post-administration, 2, 4 hours

  4. Memory-Guided

    Measures how quickly gaze is shifted directly and accurately to a remembered cue position.

    Time frame: Pre-administration, post-administration, 2, 4 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 54 non-industry phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 7 months is below that.

Counting every sponsor, half of 80 studies reached it within 29 months; a quarter within 13 and three quarters within 49.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartEst.
Dec 1, 2026was Oct 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Dec 1, 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06351540
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Dustin C Lee, PhD
Contact
dlee214@jhmi.edu
410-550-4035
Dustin C Lee, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa subsp. indica TOP

Start the discussion